Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma

NCT01721772 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

418

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: BMS-936558 (Nivolumab)
BIOLOGICAL: Placebo matching BMS-936558 (Nivolumab)
DRUG: Dacarbazine
DRUG: Placebo matching Dacarbazine

Sponsor

Bristol-Myers Squibb